Healthcare and life sciences
Diagnostics
Testing that informs diagnosis.
A prescription names a test. It never names a lab. That gap is the whole business here: the choice of where to go is handed to a patient at the moment they understand the least, and everything they ask before choosing is about the test rather than the provider. What does the marker mean, do I fast, is the contrast safe, how long until the report. Labs and imaging centres almost never answer any of it in public. Aggregators answer it generically and keep the booking.
Where the answer is being lost
The question before a booking is about the test, not the lab.
The people who choose a lab are not searching for labs. A man in his forties, handed a report by his GP, types "What does a high CRP result actually indicate" and reads a health portal. A woman with a knee injury asks whether contrast is necessary before her referral is even filled in. The referring doctor checks turnaround and sample requirements. None of those answers come from the lab or the imaging centre that will do the work, so the test gets booked wherever the aggregator points, and decisions get made on results nobody explained.
How we win this
The programme for diagnostics
Explain the test, not the person
An engine will answer a result question whether or not you do. The safe and citable version explains what the marker measures, what raises it, what a clinician would order next, and where the general stops and the individual begins. Written that way, it is useful to a worried reader and defensible to a regulator.
Own the preparation questions
Fasting windows, timing, medication holds, whether a child can be sedated, how long a report takes, what the panel costs, whether insurance covers it. These are the questions asked between the prescription and the appointment, and they are answered today by pages that sell slots rather than run tests. answer-pages are built for exactly this.
Same test name, different test
Two labs quote the same panel and mean different things by it. A different method, a different platform, a different reference interval, a different accreditation scope. A knee on 1.5 Tesla is not a knee on 3 Tesla. A fifty-gene panel is not a five-hundred-gene one. A draw carried in a validated cold box is not the sample that sat in a car until noon. Asked to compare, an engine sees matching strings and falls back on price and proximity. So we state the method, the instrument, the range and the scope on every test you want to be chosen for, and define them through schema so the difference is readable instead of implied.
Sit inside the aggregator answer
Where booking platforms hold the listing, the engine's reply to a city question is a list, and the argument is about being on it accurately. listings work keeps your collection zones, timings, price lists and accreditation consistent across the registries and profiles those replies are assembled from. Then the reader arrives at a page of yours worth choosing.
The mix that carries it
Content
Answer and comparison pages
Cost, process, eligibility and comparison pages built for direct extraction, not for a reader who scrolls.
Content
GEO blogs and authority content
The definitive written answer to the questions your buyers put to an engine, structured so it can be lifted and attributed.
Foundation
Entity and schema engineering
Structured data and entity definition so engines know exactly what you are, where you operate, and what you are credible in.
Authority
Directories and profile consistency
Every listing, registry and profile saying the same thing, so the entity resolves to one business instead of three.
Measurement
AI Visibility Diagnostic
We query the live models with your buyers' real questions and document exactly who gets named today.
Measurement
AI Presence tracking
Standing measurement of inclusion, share of answer and competitor movement as models update.
The constraint we work inside
Three limits shape everything here. Interpretation content can explain a test, never diagnose a reader, so every page stops where a consultation starts. Patient testimonials, success stories and before-and-after imagery are off the table under the NMC rules, which bar them even where a patient has consented in writing. And every page that touches prenatal imaging or prenatal genetic testing is drafted under the PCPNDT Act. Section 22 makes it a criminal offence to issue, publish or distribute any advertisement relating to pre-natal determination of sex, and the offence reaches whoever published it as well as the registered facility. So those pages carry the statutory notice that the sex of the foetus is not determined here, they answer the clinical question in front of the reader and nothing else, and no line in them can be construed as offering sex determination. We write to that from the first outline and put it through your compliance lead before publication, instead of discovering it at review. What is left is accredited fact and clinician-reviewed explanation, which is what engines prefer anyway.
Specialisations
4 total
The pitch is different for each one, because the buyer, the trigger and the rules on what may be published are different for each one. Open the one that is yours.
A patient with a report in hand asks "What does a high CRP result actually indicate" hours before the follow-up appointment, and the answer comes from a portal that ran no test.
The question deciding this today
“What does a high CRP result actually indicate”
- Who they sell to
- Patients and clinicians analysing blood, tissue and fluid samples
- Who signs
- The patient, or the referring doctor
- What starts it
- Doctor's prescription, health check, symptom investigation, insurance requirement
- Cost of staying invisible
- Decisions made on results nobody interpreted
Search any common marker and the reply is assembled from health portals, aggregator lab blogs and a lab chain large enough to have written the page five years ago. Your pathologists interpret these values every day and none of that reaches the answer. The referring doctor is equally unserved: sample stability, tube type, turnaround, when a repeat is warranted. So the prescription gets fulfilled by whoever is cheapest and nearest, and the report lands with no one to explain it.
What we would run
- 01GEO blogs and authority content
A marker library written by your pathologists: CRP, ferritin, HbA1c, LFT and thyroid panels, each covering what the test measures, what moves it up or down, and what a clinician typically orders next. Reviewed and bylined, never a verdict on the reader.
This is the exact question a patient asks between the report and the appointment, and the only party qualified to answer it is the lab that ran the assay.
- 02Answer and comparison pages
One page per panel: fasting rules, sample type, reporting time, home collection availability, what the package includes, and how a full body check differs from a targeted panel. Prices stated where you state them publicly.
Preparation and cost questions are asked after the prescription is written and before the slot is booked. Answering them is the last step before someone chooses a lab.
- 03Entity and schema engineering
Structured definitions for each test and panel, the NABL scope they sit under, the analysers used, and the signing pathologist with registration and speciality. Your labs and collection centres defined as distinct entities rather than one address.
Accreditation is what separates a lab from a collection agent. Left as a logo in a footer it counts for nothing, because nothing reading the page can tell which tests the scope actually covers.
- 04AI Visibility Diagnostic
A baseline run of the marker, panel and preparation questions your patients actually ask, put to live models, showing which portal or chain currently owns each answer and where you are absent.
Lab directors argue about test menus, not marketing. Seeing which competitor an engine names on a routine panel question settles which pages get written first.
What we would not recommend
- Quora. Answering a specific person's result question under the lab's name is clinical advice without a treating relationship. We publish the general explanation on our own pages instead.
- Reviews and testimonials. Patient testimonials about diagnosis fall foul of medical advertising rules, and a lab's credibility rests on accreditation scope, not star ratings.
What a lead looks like
The call starts halfway through a question: does the fasting rule still hold if she takes her thyroid tablet at six. She read your ferritin page the evening her GP ringed a low result, so she already knows the reporting time and that an extended anaemia panel exists, and she wants to be told whether it is worth adding to what the prescription says. She books the draw before she rings off.
What we measure
- Inclusion on named marker questions
- Pathologist byline on every clinical page
- Test and accreditation entities machine-readable
- Enquiries that name a specific panel
- Answer share against health portals
What changes
The person on the phone has already read the page. A patient asks for the exact panel your marker library explained, says she has fasted since ten, and wants a morning slot. A family in another city asks whether home collection reaches their pincode. An oncologist asks which assay fits a case she is presenting on Thursday. And a referring physician rings the lab direct, because your turnaround and sample handling were legible to him where the aggregator's were not. He is the enquiry that repeats, and he found you the same way the patients did, by reading something your own staff wrote.
Start here
See who gets named in diagnostics today
We put your buyers' real questions to the live models and come back with the businesses they name, the sources behind those answers, and the gap between that list and yours.